Publications by authors named "Guenter Auerswald"

Claim this Profile
C
Clinical, Obstetric-Gynaecological and HRQoL Data of Female VWD Patients in the WIL-QoL Study.
Susan Halimeh, Cornelia Wermes, Carolin Moorthi, Ronald Fischer, Christine Heller, Guenter Auerswald

Haemophilia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life in Adult Patients With von Willebrand Disease From Germany: Results of the WIL-QoL Study.
Sylvia von Mackensen, Carolin Moorthi, Ronald Fischer, Susan Halimeh, Christine Heller, Guenter Auerswald

Haemophilia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency.
Flora Peyvandi, Guenter Auerswald, Steven K Austin, Ri Liesner, Kaan Kavakli

Blood Rev· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study).
Toshko Lissitchkov, Anna Klukowska, Evgeny Buevich, Irina Maltceva, Guenter Auerswald

J Blood Med· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study).
Guenter Auerswald, Claudia Djambas Khayat, Oleksandra Stasyshyn, Genadi Iosava, Irina Romashevskaya

J Blood Med· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.
Rolf Ljung, Guenter Auerswald, Gary Benson, Gerry Dolan, Anne Duffy

Eur J Haematol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of inhibitors in haemophilia patients.
Christopher E Walsh, Víctor Jiménez-Yuste, Guenter Auerswald, Salvador Grancha

Thromb Haemost· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER).
Mariasanta Napolitano, Muriel Giansily-Blaizot, Alberto Dolce, Jean F Schved, Guenter Auerswald

Haematologica· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors.
Guy Young, Guenter Auerswald, Victor Jimenez-Yuste, Thierry Lambert, Massimo Morfini

Thromb Res· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A.
Guenter Auerswald, Alexis A Thompson, Michael Recht, Deborah Brown, Raina Liesner

Thromb Haemost· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homozygous Factor X gene mutations Gly380Arg and Tyr163delAT are associated with perinatal intracranial hemorrhage.
Falko H Herrmann, Marta Navarette, Lizbeth Salazar-Sanchez, Juan M Carillo, Guenter Auerswald

J Pediatr· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis